Page 2467 - Williams Hematology ( PDFDrive )

2438 Index Index 2439

Glycosyl phosphatidylinositol (GPI) anchors, human leukocyte antigens and, 357–358, for chemotherapy enhancement,
37, 1007 2356 1396
Glycosyl phosphatidylinositol (GPI)-anchor mesenchymal stromal cells for, 449–450 eosinophils and, 947
synthesis pathway, 573, 573f, with peripheral blood progenitor cells vs. in neutrophilic granulopoiesis, 939–940
578 marrow, 356 Granulocyte-monocyte progenitors, 271,
Glyoxalase 1, 701t prevention, 440, 440f, 2374 1154
GM11070, for sickle cell disease, 777t T-cell therapy and, 410 Granulocyte progenitors, 271
GM-CSF. See Granulocyte-macrophage transfusion-associated, 2377, 2388 Granulocytes
colony-stimulating factor Graft-versus-leukemia (GVL) effect, 307, 310, in chronic myelogenous leukemia, 1445,
(GM-CSF); Granulocyte-monocyte 1400, 1461 1446f
colony-stimulating factor Graft-versus-tumor effects, 359 defined, 939
(GM-CSF) Granular lymphocytes, 20f, 23 differentiation, 65
GMP. See under Granulocyte-macrophage Granulocyte colony-stimulating factor marrow, 34
progenitor (GMP) (G-CSF), 100 precursor cell kinetics, 75t
GMP140. See P-selectin for aplastic anemia, 525t, 526 release, 71–72
GNA 12/13, 1627t for chemotherapy enhancement, 1396, Granulocytic sarcoma. See Myeloid
GNAS/GNB1, 1346t, 1348 1402t (granulocytic) sarcoma
Gold salts, 2015 for evaluation of neutrophil reserves, 943 Granulocytopenia, 991. See also Neutropenia
Gonadal function, acute myelogenous in hematopoiesis, 264t Granulocytopoiesis, in newborn, 105
leukemia treatment and, 1411 for hematopoietic stem cell mobilization, Granulocytosis, 997. See also Neutrophilia
Gonadotropins, 561 73, 355 in Hodgkin lymphoma, 1610
GOT (glutamate oxaloacetate transaminase), for hypersplenism, 867 in primary myelofibrosis, 1326
193 in innate immune response, 303 Granulomatous inflammation, 279
Gout, in polycythemia vera, 1293 monocytosis and, 1097 Granulomonopoiesis, 105
Gower-1 hemoglobin, 101, 101t, 728 for myelodysplastic syndromes, 1358, 1361 Granulophysin. See CD63
Gower-2 hemoglobin, 101, 101t, 728 for neutropenia, 993, 994 Granulopoiesis, neutrophilic. See
GP. See under Glycoprotein (GP) neutropenia and, 992 Neutrophils, granulopoiesis
gp91 phox (CYBB), 1013t, 1028t, 1029 neutrophilia and, 985, 1000 Granzyme B, 204f, 205, 1565f, 1567
gp 100, 413 in neutrophilic granulopoiesis, 940 Granzymes, 1145
GPI. See Glucose phosphate isomerase (GPI); in neutrophil protein synthesis, 932 Graves disease, 518
Glycosyl phosphatidylinositol neutrophils and, 66. Gray platelet syndrome (α-storage pool
(GPI) secondary acute myelogenous leukemia deficiency), 1850, 1853, 1996,
G protein, 1016 and, 1407 2054–2055, 2055f
G-protein–coupled chemokine receptors, Granulocyte-macrophage colony-stimulating GRB2 (growth factor receptor-bound
1878 factor (GM-CSF) protein-2), 1443
G-protein–coupled receptors (GPCRs) eosinophils and, 949, 953 Green sickness, 628
in monocytes and macrophages, 1059, in erythropoiesis, 483f Griscelli syndrome, 994, 1020, 1229, 1849
1060t in hematopoiesis, 258f, 264t, 268 Group B streptococcal infection, in newborn,
in neutrophils, 1008 in innate immune response, 303 105–106
in platelet activation, 1874, 1875f in monocyte and macrophage Growth, iron deficiency and, 632
structure and function, 248f, 250 differentiation, 1077–1078 Growth arrest-specific 6 (Gas 6) protein,
G proteins, 1882–1883 monocytosis and administration of, 1097 484, 1845
GPYA, 2339 for myelodysplastic syndromes, 1358 Growth differentiation factor 15, 622, 641
GR. See Glutathione reductase (GR) natural killer cells and, 1191 Growth factor receptor-bound protein-2
Graft-versus-host disease (GVHD) neutropenia and, 992 (GRB2), 1443
acute, 370–372 neutrophilia and, 1000 Growth hormone (GH), 561, 1407
clinical features, 370–371, 1197 neutrophils and, 1008 GS. See Glutathione synthetase (GS)
pathophysiology, 371 regulation, 1444 GSH (glutathione), 694, 698, 706–707
prevention, 357, 371 vaccine therapy and, 423, 423f, 424f GSSG (glutathione disulfide), 698
risk factors, 370 Granulocyte-macrophage progenitor (GMP), GT. See Glanzmann thrombasthenia (GT)
treatment, 371–372, 429t 271 GTPases, 1059, 1833t
after allogenic hematopoietic cell Granulocyte-macrophage progenitor (GMP)- Guanine-nucleotide exchange factor (GEF),
transplantation, 1399–1400, 2374 33 (thrombospondin N-terminal 1063f
chronic, 356, 372, 1197 fragment), 1873 Guanosine triphosphate-binding protein
dendritic cells in, 310 Granulocyte-monocyte colony-stimulating defects, 2057
gene therapy and, 440, 440f factor (GM-CSF), 100 Guillain-Barré syndrome, 1265

Kaushansky_index_p2393-2506.indd 2438 9/21/15 3:22 PM